Takeda's net profit plunges 24% as Prevacid slumps
This article was originally published in Scrip
The negative trends of the first quarter continued through to Takeda's results for the first half ended 30 September, when total net sales at Japan's largest pharmaceutical company fell by 5% to ¥714.0 billion ($8.78 billion).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.